SBIR Phase I: Sustained Pulmonary Release of Nanoencapuslated Proteins for Counter Bioterrorism Applications

SBIR 第一阶段：用于反恐应用的纳米封装蛋白质的持续肺部释放

• 批准号: 0539720
• 负责人: Deepika Singh
• 金额: --
• 依托单位: SINMAT, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-01-01 至 2006-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0539720&HistoricalAwards=false
• 关键词: SBIR; Phase; Sustained; Pulmonary; Release

This Small Business Innovation Research (SBIR) project focuses of novel method for sustained pulmonary release of protein based antitoxins for counter bioterrorism applications. There is a significant need of therapeutic treatments against bioterrorism agents such as anthrax, cholera, tetanus, diphtheria, ricin, etc. These biotoxin agents are lethal in very small amount ranging from 0.001 microg / kg to 0.1 microg / kg. Typically antibiotics are only effective in neutralizing the bioterrorism agent (e.g. bacterium) and not the released protein toxin. Significant challenges currently exist in the development of therapeutic methods that can neutralize the protein biotoxin during and after it has been released in the human environment . The overall goal of this exploratory project is to develop and demonstrate the effectiveness of completely nano-encapsulated hydrophilic proteins (such as antibodies, enzymes or protein based cell receptor) that can be delivered via the pulmonary route. Such particles will be synthesized using a novel semiconductor film deposition technique, which has until recently not been explored for pharmaceutical applications.Sustained Pulmonary release of proteins can not only neutralize biotoxin agents but also deliver other drugs. The development of solvent-free drug encapsulation systems has the potential to be used not only in pulmonary-based applications but also in injectable and oral delivery of peptide, traditional non-peptide and gene-therapy based drugs. Efficient delivery of proteins and peptides is required for a number of diseases such as diabetes, cystic fibrosis, and genetic protein deficiency disorders. Thus this project could lead to development of a platform technology for delivery of macromolecules for several diseases.

这个小企业创新研究（SBIR）项目的重点是新的方法持续肺部释放的蛋白质为基础的抗毒素用于反生物恐怖主义的应用。非常需要针对生物恐怖剂（例如炭疽、霍乱、破伤风、白喉、蓖麻毒素等）的治疗性处理。这些生物毒素剂在0.001微克/千克至0.1微克/千克的非常小的量下是致命的。通常抗生素仅在中和生物恐怖剂（例如细菌）而不是释放的蛋白质毒素方面有效。目前在开发治疗方法中存在重大挑战，该治疗方法可以在蛋白质生物毒素释放到人类环境中期间和之后中和蛋白质生物毒素。该探索性项目的总体目标是开发和证明可通过肺部途径递送的完全纳米封装的亲水性蛋白质（如抗体、酶或基于蛋白质的细胞受体）的有效性。此类颗粒将使用新型半导体薄膜沉积技术合成，该技术直到最近才被探索用于制药应用。蛋白质的肺部持续释放不仅可以中和生物毒素，还可以输送其他药物。无溶剂药物包封系统的开发不仅有可能用于基于肺部的应用，而且有可能用于肽、传统非肽和基因治疗药物的注射和口服递送。蛋白质和肽的有效递送对于许多疾病如糖尿病、囊性纤维化和遗传蛋白质缺乏症是必需的。因此，该项目可能会导致开发一种平台技术，用于为几种疾病提供大分子。